Romney Humphries

Romney Humphries

Romney Humphries is a diplomate of the American Board of Medical Microbiology and the Chief Scientific Officer, Accelerate Diagnostics. Her research interests include antibiotic resistance and antimicrobial susceptibility testing.

It takes courage to try something new when many view new ideas as strange. Compare leadership in 'intermediate susceptibilily' interpretation to leadership in a festival dance party - who needs more courage, leaders or their early followers?

Monday, 14 May 2018 16:54

Is It Really about the MIC?

The use of beta-lactamase combination agents like piperacillin-tazobactam to treat ESBL-producing isolates has always been somewhat controversial. Results from the new MERINO clinical trial suggest reviving ESBL testing. Romney Humphries explains why continued protocol tweaking helps laboratorians move closer to the perhaps-impossible goal of perfecting ESBL screening.

In clinical microbiology, “intermediate” —the state of neither up nor down—means both “diagnostic uncertainty” AND “susceptible with increased exposures.” How can we cut one and not lose the other?

Fosfomycin susceptibility testing is a challenge for laboratories. The testing intricacies for fosfomycin are discussed.

Taxonomic splitting of bacterial species can change AST recommendation. What should clinical microbiologists do when new species are assigned to the Enterobacteriaceae or when species are renamed? Romney Humphries addresses this problem in this week's Bugs & Drugs.

How does one interpret an MIC if there is no clinical breakpoint for the tested drug/bug combination? Some tools, including the epidemiological cut-off value and PK/PD breakpoints can help!

The ever-changing CLSI recommendations for colistin testing (and one lab director’s endless frustration with this!) are reviewed.

Have you ever encountered an isolate of Staphylococcus that gave you seemingly discordant susceptibility results? You'd be lying if you said "no"! Learn how your lab can sort out staphylococcal susceptibility testing dilemmas.